Client news: Miracor announces FDA IDE approval for PiCSO pivotal study

AGIO Capital
One of our clients, Miracor Medical, has made the announcement of the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI).
Miracor Medical is a Belgian company, located in Awans, that specializes in the treatment of cardiac diseases. In 2020, we supported Miracor in the raising of their series E financing round, which supported the development of the PiCSO technology in further stages. Click here to read the full report on the series E raising.
Want to read the full press release on the approval? Click here.  

Our specialists in the field